短链脂肪酸:肠-大脑轴对抗AD的重要组成部分
Yan Huang1, Yi Feng Wang1, Jing Miao2
1College of Life Science and Technology, Xinjiang University, Urumqi 830000, China.
概括
来自肠道细菌的短链脂肪酸 (SCFA) 通过影响肠-大脑轴,对阿尔茨海默病 (AD) 治疗有希望. 本研究探讨了SCFA机制及其通过微生物和代谢调节对AD的积极影响.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特点是认知能力下降,由大脑变化和细胞死亡驱动.
- 肠道微生物群通过食纤维发酵产生短链脂肪酸 (SCFA),通过肠-大脑轴影响生理和病理过程.
研究的目的:
- 研究SCFA和肠道细菌在阿尔茨海默病中的作用.
- 阐明SCFA影响AD进展和潜在治疗途径的机制.
主要方法:
- 在AD病例中对SCFA水平和微生物组成的比较分析与对照 (人类和小鼠模型).
- 对AD中主要SCFA的治疗机制的综述和总结.
- 阐明SCFA在维持肠道菌群平衡,免疫调节和代谢调节方面的功能.
主要成果:
- 在患有AD的人群中,观察到SCFA概况和肠道微生物群落的显著差异.
- 关键的SCFA通过多种生物途径证明了AD的潜在治疗益处.
- 在调节肠道微生物群,免疫系统和新陈代谢方面,SCFA起着至关重要的作用,所有这些都与AD有关.
结论:
- 肠道细菌及其代谢物SCFA是阿尔茨海默病中肠-大脑轴的组成部分.
- 准肠道微生物群和SCFA生产是对AD的有希望的治疗策略.
- 了解肠道健康和大脑功能之间的相互作用对于AD管理至关重要.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
10.2K
相关概念视频
Role of Neurotransmitters in Memory
531
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
531
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
120
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120
